HKUOC

2025年10月17日，香港聯合腫瘤中心（HKUOC）聯同香港腫瘤學研究學會（HKOSG）於佐敦盛樂中心成功舉辦「肺癌精準治療 基因檢測改寫生命」講座，吸引超過百位肺癌患者、康復者及家屬參與。主講嘉賓為臨床腫瘤科專科李宇聰醫生，講座深入介紹基因檢測技術如何為肺癌患者帶來新希望。

A new era of precision treatment of lung cancer: Genetic Testing rewrites the Story of life｜Cancer Lecture series (2025/10/17)

Leave a Comment / ALK gene, EGFR gene /

On October 17, 2025, the United Cancer Centre of Hong Kong (HKUOC) and the Hong Kong Society of Oncology Research (HKOSG) successfully held a seminar on "Precision Treatment of Lung Cancer Genetic Testing Rewrites Life" at the Jordan Shing Lok Centre, attracting more than 100 lung cancer patients, survivors and their families to participate. The keynote speaker was Dr. Li Yu Chung, Jacky, a specialist in clinical oncology. The lecture introduced in depth how genetic testing technology can bring new hope to lung cancer patients.

A new era of precision treatment of lung cancer: Genetic Testing rewrites the Story of life｜Cancer Lecture series (2025/10/17) Read More »

DURIGAST試驗FD組與FDT組療效對比數據表格，顯示4個月無進展生存率、中位PFS、客觀緩解率、中位OS及1年以上疾病控制率

Durvalumab consolidates treatment breakthroughs: Significantly prolongs the survival of confined small cell lung cancer

Leave a Comment / Lung cancer, AKT gene, ALK gene, BRAF gene, BRCA gene, CD40 gene, CD73 gene, EGFR gene, EMT gene, ER+/HER2-gene, ESR1 gene, FGFR gene, HER2 gene, HER3 gene, HRAS gene, IDH1 gene, IDHI gene, PD-1 gene, PD-L1 gene, PD-L2 gene, RAS gene, ROS1 gene, Gene classification articles, Targeted therapy /

The third phase of the ADRIATIC study showed that Durvalumab consolidation therapy significantly extended the survival of patients with limited-stage small cell lung cancer (SCLC), with a median total survival of 56 months, which was significantly improved compared to 33 months in the placebo group. This article introduces the research data, clinical significance and treatment prospects in detail to help you understand the latest advances in immunotherapy for lung cancer.

Durvalumab consolidates treatment breakthroughs: Significantly prolongs the survival of confined small cell lung cancer Read More »

Tovorafenib為攜帶BRAF基因變異的兒童低級別膠質瘤患者提供突破性治療

Tovorafenib approved by the FDA: breakthrough treatment for low-grade glioma in children with BRAF mutation

Leave a Comment / Drug information, BRAF gene, Targeted therapy, Cancer treatment, Cancer drugs, Rare cancer, Drugs for brain diseases, brain cancer, Glioma drugs /

The FDA accelerated the approval of Tovorafenib (Ojemda) for the treatment of low-grade gliomas in children with recurrent or refractory BRAF variants on April 23, 2024. This article introduces its efficacy data, safety characteristics and clinical application guidelines in detail. It is suitable for reference by parents and medical staff who are concerned about the treatment of brain tumors in children. Learn more about the latest information about this breakthrough targeted therapy.

Tovorafenib approved by the FDA: breakthrough treatment for low-grade glioma in children with BRAF mutation Read More »

Revumenib治療急性白血病療效數據

A new generation of Menin inhibitors revolutionizes the treatment of acute leukemia, giving Hong Kong patients new hope

Leave a Comment / Medications for acute myeloid leukemia, Targeted therapy, Cancer treatment, Leukemia drugs, Drug information /

The 2024 Annual meeting of the American Society of Hematology will reveal the safety and efficacy of a new generation of Menin inhibitors in the treatment of acute myeloid leukemia (AML). Drugs such as Ziftomenib and Bleximenib showed significant complete remission rates for KMT2A rearrangement and NPM1 mutations, bringing new hope to patients in Hong Kong. Learn more about clinical trial data and treatment prospects.

A new generation of Menin inhibitors revolutionizes the treatment of acute leukemia, giving Hong Kong patients new hope Read More »

Retifanlimab-dlwr治療默克爾細胞癌的突破性療效

Retifanlimab-dlwr is used to treat metastatic or recurrent locally advanced Merkel cell carcinoma

Leave a Comment / Skin cancer medication, PD-1 gene, Immunotherapy, solid cancer, Malignant cancer drugs, Advanced tumor drugs, Cancer treatment, Skin cancer, Rare cancer, Drug information /

The U.S. FDA accelerated the approval of the PD-1 antibody retifanlimab-dlwr for the treatment of metastatic or recurrent locally advanced Merkel cell carcinoma in March 2023. The POD1UM-201 clinical trial showed a 52% objective remission rate, bringing new treatment options to patients with this rare skin cancer. Understand medication recommendations, safety data, and treatment precautions.

Retifanlimab-dlwr is used to treat metastatic or recurrent locally advanced Merkel cell carcinoma Read More »

Zenocutuzumab 用於治療 NRG1 基因融合癌症的臨床研究成果。

Zenocutuzumab: FDA approves new bispecific antibody for the treatment of NRG1 gene fusion cancer

Leave a Comment / Drug information, HER2 gene, HER3 gene, NRG gene, Targeted therapy, Cancer treatment, Lung cancer drugs, Pancreatic cancer drugs, Non-small cell lung cancer, Targeted therapy /

Zenocutuzumab was approved by the U.S. FDA for the treatment of patients with lung cancer and pancreatic cancer with NRG1 gene fusion, marking a breakthrough in cancer treatment.

Zenocutuzumab: FDA approves new bispecific antibody for the treatment of NRG1 gene fusion cancer Read More »

Vorasidenib IDH1/2抑制劑分子結構，用於治療IDH突變型星形細胞瘤及少突膠質細胞瘤

The U.S. Food and Drug Administration (FDA) approved the IDH1/2 inhibitor Vorasidenib for patients with specific astrocytoma or oligodendrocytoma

Leave a Comment / IDH1 gene, Malignant cancer drugs, Uncategorized, Targeted therapy, Cancer treatment, Drugs for brain diseases, brain cancer, Glioma drugs, Drug information /

The U.S. FDA approved the IDH1/2 inhibitor Vorasidenib for use in patients with specific astrocytoma and oligodendrocytoma in August 2024. The INDIGO clinical trial has shown that it significantly prolongs the survival period without progress, bringing new treatment options to patients with IDH mutant glioma. Learn about applicable patients, medication recommendations, and safety information.

The U.S. Food and Drug Administration (FDA) approved the IDH1/2 inhibitor Vorasidenib for patients with specific astrocytoma or oligodendrocytoma Read More »

DURIGAST試驗FD組與FDT組療效對比數據表格，顯示4個月無進展生存率、中位PFS、客觀緩解率、中位OS及1年以上疾病控制率

Immunotherapy combined with chemotherapy for the treatment of advanced gastric cancer/gastroesophageal junction adenocarcinoma: Analysis of the results of DURIGAST PHASE II trial

Leave a Comment / stomach cancer, PD-1 gene, PD-L1 gene, Immunotherapy, Chemotherapy, solid cancer, Malignant cancer drugs, Advanced tumor drugs, Targeted therapy, Cancer treatment, Stomach cancer drugs, Gastroesophageal adenocarcinoma medications /

研究概況 法國多中心非對照II期臨床試驗（PRODIGE 59-FFCD 1707-DURIGAST）評估了F

Immunotherapy combined with chemotherapy for the treatment of advanced gastric cancer/gastroesophageal junction adenocarcinoma: Analysis of the results of DURIGAST PHASE II trial Read More »

Tovorafenib為攜帶BRAF基因變異的兒童低級別膠質瘤患者提供突破性治療

FDA accelerated approval of Tovorafenib for the treatment of low-grade glioma patients with recurrent or refractory BRAF gene variants in children

Leave a Comment / Glioma drugs, BRAF gene, Genetic testing, Genetic diagnosis, solid cancer, Targeted therapy, Cancer treatment, Cancer drugs, Rare cancer, Drugs for brain diseases, brain cancer, tumor, Drug information /

The FDA accelerated the approval of the RAF inhibitor Tovorafenib (Ojemda) in April 2024 for the treatment of patients with recurrent/refractory low-grade glioma in children carrying BRAF gene variants. THE FIREFLY-1 study SHOWED A TOTAL REMISSION RATE OF 51% AND A MEDIAN REMISSION DURATION OF 13.8 MONTHS, PROVIDING THE FIRST BRAF TARGETED TREATMENT OPTION FOR CHILDREN WITH BRAIN TUMORS. The United Cancer Centre of Hong Kong provides professional child cancer consultation.

FDA accelerated approval of Tovorafenib for the treatment of low-grade glioma patients with recurrent or refractory BRAF gene variants in children Read More »